Which Weight Loss Injection Suits Your Lifestyle?
Weight Loss Injections Wegovy vs Mounjaro: Understanding the Key Differences
When comparing weight loss injections, Wegovy and Mounjaro represent different approaches to appetite regulation and metabolic support. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones, whilst Mounjaro contains tirzepatide, which targets both GIP and GLP-1 receptors for dual hormone pathway activation. This fundamental difference in mechanism means some patients may respond better to one treatment over the other, making professional guidance essential.
The dosing schedules also differ significantly between these weight loss injections. Wegovy follows a 5-dose escalation from 0.25mg to 2.4mg maintenance over 16 weeks, whilst Mounjaro uses 6 doses ranging from 2.5mg to 15mg maximum. Both require weekly injections and gradual dose increases to minimise side effects, but the timing and strength variations mean your prescriber will consider your individual tolerance and response when recommending the most suitable option.
Transparent Pricing for Weight Loss Injections Wegovy and Mounjaro
EverydayMeds offers competitive pricing for both weight loss injections, with Wegovy starting at £79.99 for the 0.25mg starter dose and progressing to £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles provide convenience for dose escalation, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, helping you plan your initial treatment journey. New customers can apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to access these prices.
Mounjaro pricing follows a different structure reflecting its unique dosing schedule, with all prices clearly displayed during your clinical assessment. Both treatments qualify for our next-day cold-chain delivery service, ensuring temperature-controlled transport to maintain medication effectiveness. Our bundle options for both weight loss injections provide supply security and reduce the frequency of orders, particularly beneficial during dose escalation phases when consistent supply is crucial.
Clinical Evidence for Weight Loss Injections Wegovy Effectiveness
In clinical trials, patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved significant weight loss results. The landmark STEP 1 trial (Wilding et al., NEJM, 2021) demonstrated approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo. STEP 5 showed sustained weight loss of 15.2% at two years, indicating long-term effectiveness when treatment continues.
The SELECT cardiovascular outcomes trial revealed an additional benefit, with Wegovy showing a 20% reduction in major cardiovascular events (HR 0.80) in eligible patients. NICE TA875 recommends Wegovy for weight management with specialist support, recognising its clinical evidence base. These results reflect outcomes when weight loss injections Wegovy is used as prescribed with lifestyle modifications.
How Weight Loss Injections Wegovy Works in Your Body
Wegovy functions as a GLP-1 receptor agonist, mimicking incretin hormones naturally produced in your intestine after eating. This mechanism promotes feelings of fullness and satiety, helping you feel satisfied with smaller meal portions and reducing between-meal cravings. The medication works on appetite centres in your brain, particularly the hypothalamus, where hunger and satiety signals are processed. Unlike stimulant-based appetite suppressants, Wegovy works with your body's natural hormone pathways to support appetite regulation. This prescription-only medicine requires weekly subcutaneous injection using the convenient FlexTouch pen device, designed for easy self-administration. The gradual dose escalation helps your body adjust to the medication whilst minimising gastrointestinal side effects that can occur when starting GLP-1 treatments.
Ordering Weight Loss Injections Wegovy Through EverydayMeds
Our streamlined ordering process begins with a comprehensive 3-minute clinical assessment covering your medical history, current medications, and weight management goals. This information is reviewed by our qualified prescribers, with standard review completed within 3 working days or express review available within 24 hours for urgent requirements. Once approved, your weight loss injections Wegovy are dispatched via next-day delivery using specialist cold-chain transport to maintain the required 2-8°C temperature range. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance and medication authenticity. You'll receive tracking information and temperature monitoring confirmation, plus comprehensive injection guidance and ongoing support throughout your treatment. The entire process is designed for convenience whilst maintaining the highest standards of pharmaceutical care and patient safety.
Storage and Practical Considerations for Weight Loss Injections Wegovy
Wegovy requires refrigerated storage at 2-8°C before first use, but offers superior travel convenience with 6 weeks room temperature stability once removed from the fridge, compared to Mounjaro's 21-day limit. The FlexTouch pen design provides accurate dosing with clear dose display and simple operation, making weekly injections straightforward for most patients. Each pen contains 4 doses, requiring replacement monthly during maintenance therapy, with our delivery schedule designed to ensure continuous supply. The dose escalation protocol is mandatory and cannot be accelerated, starting with 0.25mg for 4 weeks before progressing through each strength to reach the 2.4mg maintenance dose. Injection sites should be rotated between thigh, upper arm, and abdomen areas to prevent lipodystrophy, with comprehensive injection training provided with your first prescription. This prescription-only medicine requires careful handling and proper disposal of used pens through appropriate pharmaceutical waste channels.
Weight Loss Injections Wegovy vs Mounjaro: Making the Right Choice
The decision between these weight loss injections often comes down to individual response patterns and lifestyle factors. Wegovy's single-hormone approach may suit patients who respond well to GLP-1 stimulation, whilst Mounjaro's dual-hormone mechanism might benefit those requiring more comprehensive metabolic support. Some patients find Wegovy's longer room temperature storage particularly advantageous for travel or work schedules, whilst others prefer Mounjaro's different dosing strengths and escalation pattern.
Both treatments require similar lifestyle commitments including reduced-calorie diet and increased physical activity, but side effect profiles can vary between individuals. Your prescriber will consider factors including your medical history, concurrent medications, previous weight loss treatment responses, and personal preferences when recommending the most suitable option. EverydayMeds' unique position offering both weight loss injections means you can switch between treatments if needed, with full prescriber support throughout your weight management journey.
Start Your Weight Loss Journey with Expert Support
EverydayMeds combines clinical expertise with convenient access to both leading weight loss injections Wegovy and Mounjaro through our comprehensive service. Our qualified prescribers provide individualised treatment recommendations based on your specific needs and circumstances, ensuring optimal treatment selection and ongoing support. With transparent pricing, reliable supply chains, and commitment to pharmaceutical excellence, we make prescription weight management accessible and straightforward. Use discount code FIRST40 for new customers or DOSE25 for returning customers at checkout to access our competitive pricing. Your weight loss journey deserves professional support - start your clinical assessment today at https://everydaymeds.co.uk/collections/weight-loss and discover which treatment option suits your lifestyle and goals. Both treatments are available with next-day delivery once approved, helping you begin your transformation without delay.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
